PTC Therapeutics Inc. recently delivered a presentation highlighting their achievements and progress in 2024 and outlining plans for 2025. The company successfully met all development milestones in 2024, achieved a strong cash position, and recorded outstanding revenue performance, with a total revenue of $807 million. In 2024, PTC submitted four U.S. regulatory approval applications, including the AADC Gene Therapy BLA, which was approved, and three NDAs for Sepiapterin PKU, Translarna nmDMD, and Vatiquinone Friedreich's Ataxia, all of which were accepted. The company's advancements stem from their innovative scientific platforms. You can access the full presentation through the link below.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. PTC Therapeutics Inc. published the original content used to generate this news brief on June 03, 2025, and is solely responsible for the information contained therein.